Comparative Pharmacology
Head-to-head clinical analysis: CARNEXIV versus TIKOSYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARNEXIV versus TIKOSYN.
CARNEXIV vs TIKOSYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CARNEXIV is a formulation of carbidopa and levodopa; levodopa is converted to dopamine in the brain, replenishing depleted dopamine in the striatum, while carbidopa inhibits peripheral decarboxylation of levodopa, increasing central availability.
Selective class III antiarrhythmic agent; blocks cardiac potassium channels (IKr), prolonging action potential duration and effective refractory period.
1 mg intravenously once daily for 7 days, followed by 1 mg orally once daily for 7 days.
500 mcg orally twice daily for atrial fibrillation/flutter conversion and maintenance of sinus rhythm.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours in patients with normal renal function; prolonged in renal impairment (up to 24-36 hours with CrCl <30 mL/min)
10 hours (terminal) in patients with normal renal function; prolonged to up to 42 hours in severe renal impairment; clinically relevant for dosing interval adjustment.
Renal (approximately 70% as unchanged drug and metabolites), biliary/fecal (approximately 25-30%)
Renal: 80% as unchanged drug; biliary/fecal: 20% (metabolites and minor parent drug).
Category C
Category C
Antiarrhythmic Agent
Antiarrhythmic Agent